Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

JAMA

Volumn 287, Issue 13, 2002, Pages 1653-1661

  Marek, Kenneth ^a   Seibyl, John ^a   Shoulson, Ira ^b   Holloway, Robert ^c   Kieburtz, Karl ^c   McDermott, Michael ^c   Kamp, Cornelia ^c   Shinaman, Aileen ^c   Fahn, Stanley ^d   Lang, Anthony ^e   Weiner, William ^f   Welsh, Mickie ^g  

^a INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^b CALM PD   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e TORONTO WESTERN HOSPITAL   (Canada)

^f UNIVERSITY OF MARYLAND   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBIDOPA; DOPAMINE TRANSPORTER; IODINE 123; LEVODOPA; PHENYL GROUP; PRAMIPEXOLE; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; IMAGING; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

EID: 0037012478     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.13.1653     Document Type: Article

References (43)

1. Brain dopamine and the syndromes of Parkinson and Huntington, clinical, morpological, and neurochemical correlates
2. Ageing and Parkinson's disease: Substantia nigra regional selectivity
3. The neuropathological basis of different clinical subgroups of Parkinson's disease
4. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions
5. Parkinson disease, the effect of levodopa, and the ELLDOPA trial
6. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist
7. Dopamine agonists and neuroprotection in Parkinson's disease
8. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole
9. Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's disease
10. 123I]FP-SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease
11. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography
12. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease
13. [l-123]CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease
14. Separating Parkinson's disease from normality: Discriminant function analysis of [18F] dopa PET data
15. 123I] beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression
16. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET
17. Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT
18. Rate of progression in Parkinson's disease: A 6-[18F]fluoro-L-dopa PET study
19. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β-CIT SPECT study
20. Rate of cell death in parkinsonism indicates active neuropathological process
21. Design of a clinical trial comparing pramipexole to levodopa in early PD (CALM-PD)
22. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial
23. 123I]β-CIT) in nonhuman primates: Pharmacokinetics, biodistribution, and SPECT brain imaging coregistered with MRI
24. A method for attenuation correction in computed tomography
25. 123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease
26. Unified Parkinson's disease rating scale
27. Parkinsonism: Onset, progression and mortality
28. Core Assessment Program for Intracerebral Transplantations (CAPIT)
29. 123I]beta-CIT: Pharmacological characterization of brain uptake in nonhuman primates
30. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease
31. Experimental therapeutic of neurodegenerative disorders: Unmet needs
32. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
33. Imaging: A molecular map for neurodegeneration
34. Relative rates of progression of early Parkinson's disease patients started on either a dopamine agonist (ropinirole) or levodopa: 2-Year and 5-year follow-up 18F-DOPA findings
35. Age-related decline in dopamine transporters: Analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries
36. Novel radioligands for the dopamine transporter demonstrate the presence of intrastriatal nigral grafts in the MPTP-treated monkey: Correlation with improved behavioral function
37. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease
38. 123I]β-CIT
39. Intent-to-treat analysis for longitudinal studies with drop-outs
40. Are dopamine receptor agonists neuroprotective in Parkinson's disease
41. 123I]β-CIT and SPECT assessment of progression in early and late Parkinson's disease
42. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
43. The response of levodopa in Parkinson's disease: Imposing pharmacological law and order